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Multiple sclerosis (MS) is a progressive autoimmune disease characterized by T-cell
mediated demyelination in central nervous system (CNS). Experimental autoimmune
encephalomyelitis (EAE) is a widely used in vivo disease model of MS. Glucocorticoids
such as dexamethasone (dex) function as immunosuppressants and are commonly
used to treat acute exacerbations of MS. Dex is also often used as a positive control
in EAE studies, as it has been shown to promote motor behavior, inhibit immune cell
infiltration into the CNS and regulate the activation of glial cell in EAE. This study further
validated the effects of intravenously administrated dex by time-dependent fashion in
EAE. Dex postponed clinical signs and motor defects in early stages of EAE. Histological
analysis revealed that the degeneration of myelin and axons, as well as the infiltration of
peripheral immune cells into the white matter of spinal cord was inhibited by dex in early
stages of EAE. Additionally, dex-treatment delayed the neuroinflammatory activation
of microglia and astrocytes. Furthermore, this study analyzed the expression of the
neurotrophic factor mesencephalic astrocyte-derived neurotrophic factor (MANF) in
EAE, and the effect of treatment with dex on MANF-expression. We show that in dex-
treated EAE mice expression MANF increased within myelinated areas of spinal cord
white matter. We also show that intravenous administration with hMANF in EAE mice
improved clinical signs and motor behavior in the early stage of EAE. Our report gives
insight to the progression of EAE by providing a time-dependent analysis. Moreover, this
study investigates the link between MANF and the EAE model, and shows that MANF
is a potential drug candidate for MS.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous
system (CNS). It affects over 2.8 million patients worldwide (Reich et al., 2018). Its pathogenesis
involves the activation of both peripheral and glial immune systems as a response to sensitization
to endogenous myelin, resulting in infiltration to the CNS by peripheral mononuclear cells and an
increase in pro-inflammatory signaling in both astrocytes and microglia in the CNS (Correale and
Farez, 2015; Chu et al., 2018; Ponath et al., 2018). Experimental autoimmune encephalomyelitis
(EAE) is one of the oldest neurological disease models in existence and is widely used to screen
pharmacological compounds searching for drug candidates for MS. It involves the immunization
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of a target animal’s immune system against myelin via the
injection of myelin components, such as myelin basic protein
(MBP), proteolipid protein (PLP) or myelin oligodendrocyte
glycoprotein (MOG) (Ransohoff, 2012). This immunization
results in a CD4+ T-cell driven inflammatory attack on the
CNS, which induces paralytic demyelination. EAE is a very
flexible model, and can be adjusted to utilize different animal
species, immunizing components, target cell types and disease
progressions. The most common model remains the C57BL/6
mouse EAE model, which features immunization with residues
35–55 of the MOG peptide emulsified in Freund’s adjuvant,
combined with injections with pertussis toxin. This results in
a reproducible, monophasic disease course (Ransohoff, 2012).
EAE models have in a few cases been used successfully in the
preclinical development of MS therapeutics (Yednock et al., 1992;
Brinkmann et al., 2002), but have generally been a poor predictor
of drug efficiency (Steinman and Zamvil, 2006; Constantinescu
et al., 2011; Lassmann and Bradl, 2017).
Shortcomings in predictiveness are believed to be caused by
key differences in the pathology of MS and EAE. While pathology
in MOG35–55/PTX immunized EAE mice is driven by CD4+ T
cells, and B cells play a very minor role, clonally expanding CD8+
T cells dominate lesions in MS and targeting B cells has been
therapeutically successful (Babbe et al., 2000; Hauser et al., 2008;
Kappos et al., 2011). On the other hand, MS is not induced by a
single antigen, and immunization with different components can
produce varied immune responses. Immunization with the MP4
MOG-PLP fusion protein, for example, shows more involvement
by B cells and CD8+ T cells than single-antigen immunized EAE
models (Kuerten et al., 2006).
MS cannot be cured. It is currently only treated with
immunomodulatory drugs that either reduce the number of
peripheral immune cells infiltrating the CNS, or shift their
phenotype toward a more anti-inflammatory state (Faissner and
Gold, 2018). Corticosteroids (CSs) such as methylprednisolone
and dexamethasone (dex) are used as first-line therapies
during acute exacerbations (Smets et al., 2017). The anti-
inflammatory mechanism of CSs is mediated through a binding
to glucocorticoid nuclear hormone receptors located in the
cytosol, leading to the translocation of the activated receptor to
the nucleus, where it regulates glucocorticoid response elements
(GREs). The activated receptors also directly inhibit general
pro-inflammatory cytokine pathways, such as nuclear factor-
kappa B (NF-κB). CSs can additionally bind to cell membrane
components, inducing rapid anti-inflammatory non-genomic
transduction cascades (Panettieri et al., 2019). Dex is often
utilized as a positive control in EAE studies, because it reliably
reduces motor function loss, delays the peak of the disease,
preserves myelin, and inhibits immune cell infiltration (Donia
et al., 2010; Dos Santos et al., 2019).
Neurotrophic factors (NTFs) play an important role in
CNS, regulating cellular processes such as differentiation and
proliferation. In states of disease, they show protective and
restorative effects. In EAE mice, knocking out CNTF (ciliary
neurotrophic factor) increases oligodendrocyte apoptosis and
negatively influenced disease progress and recovery compared
to the process in wild type mice (Linker et al., 2002).
Several NTFs have been considered as therapeutic agents for
neurological disease and injury (Pöyhönen et al., 2019), including
mesencephalic astrocyte-derived neurotrophic factor (MANF)
(Petrova et al., 2003), which has been reported to possess
protective and restorative effect in the peripheral nervous system
(PNS) and CNS in disease animal models (Voutilainen et al.,
2009; Lindahl et al., 2014; Mätlik et al., 2018). The association and
potential therapeutic of MANF in MS and its disease models has
not been investigated before.
Our report characterizes the effect of intravenously
administered dex on the pathological mechanisms and
progression of EAE by providing a time-dependent analysis
of its impact on neuroinflammation and demyelination in the
C57BL/6 model. It uncovers a regulation of MANF by dex
during EAE and investigates the time-dependent expression of
MANF in EAE mice. It is also the first examination of the effects
of treatment with MANF on disease progression and motor
behaviors in the MOG35−55/CFA immunized EAE mice model.
MATERIALS AND METHODS
Animals
Mice utilized in this experiment were C57BL/6 obtained from
Envigo. Upon initiation of the experiment, the male mice were
7 weeks old and weighed approximately 25 g. Animal were
housed under a 12:12 light:dark cycle. Water and food were
available ad libitum. Experiment groups divided in the following
manner: for effects of dex in a time-dependent manner, naïve
control (n = 7), EAE+ vehicle (n = 23), and EAE+Dex (n = 26);
for study into treatment with human MANF, EAE + vehicle
(n = 10), EAE + hMANF 1.5 µg (n = 10), and EAE + hMANF
3 µg (n = 9); for study into effects of dex in naïve mice, naïve
controls (n = 6), Dex (n = 21).
EAE Induction
EAE was induced using the EAE induction kit for C57BL/6
mice (EK-2110, Hooke Laboratories). Induction of EAE
was performed according to kit instructions. Mice were
subcutaneously injected into the upper and lower backs with
MOG35−55 peptides emulsified with complete Freund’s adjuvant
(CFA) emulsion. Additionally, mice received 200 ng of pertussis
toxin (PTX, kit component) intraperitoneally (i.p.) at 2 and 24 h
after MOG35−55/CFA injection. For naïve mice, CFA-MOG/PTX
was replaced with PBS. The clinical scores and body weight of
mice were evaluated daily. Clinical scoring followed a scale of
(0)–(5), in which (0) represents no apparent motor symptoms
or paralysis, (1) represents a completely limp tail, (2) represents
weakened hind legs, (3) represents completely paralyzed hind
legs, (4) represents partial front leg paralysis, and (5) represents
death from paralysis. Mice that were scored at 2.0 or higher
were provided with cotton bedding and soft food. Mice that
were scored over 3.0 received 0.5 ml of saline to recover from
dehydration. Treatments were given to mice as 100 µl injections
in the tail vein (i.v.) every second day, starting on day 2 after
EAE induction, under isoflurane anesthesia (4% induction, 2–3%
maintenance). Dex groups received a dose of approximately
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4.3 mg/kg of dex (D1159, Sigma) from 2 to 16 dpi, and 5 mg/kg
from 16 to 28 dpi. This dose was calculated based on mean group
weights, and Supplementary Figure 1 represents the raw data
for body weight of each group. Other groups were given either
human MANF (1.5 or 3 µg, Cat: P–101–100, icosagen, Estonia)
dissolved in PBS (B. Braun Medical, Finland), or vehicle (PBS).
Analysis of Motor Behavior
The rotarod (Ugo Basile) and open field (ENV-520, Med
Associates Inc.) tests were carried out to investigate motor
function deficit. In the rotarod test, mice were trained once a day
for 3 days on an accelerating rotating platform (from 4 to 40 rpm
for a maximum of 300 s). Once mice fell off from the rotating rod,
the latency to fall (seconds it takes for the mouse to drop from
the rod) was recorded. After training, experimental groups were
divided based on latency to fall. After EAE induction, mice were
tested at an interval of 7 days. In the open field-test, mice were
trained once in the locomotor activity chamber for 1 h before
EAE induction. After EAE induction, travel distance and rearing
activity of mice in the open-field chamber was measured for 1 h
at an interval of 7 days.
Immunohistochemistry
Mice were anesthetized by sodium pentobarbital (Mebunat,
Orion Pharma, Finland) and transcardially perfused with
phosphate-buffered saline (PBS) on days 7, 14, 21, and 28 after
induction. Following perfusion with PBS, lumbar spinal cords
were extracted and post-fixed in 4% paraformaldehyde (PFA,
Sigma) for 48 h. Samples were then paraffinized and embedded in
paraffin and sectioned into 16 µm transverse (spinal cord) slices
placed on glass slides. Before immunohistochemical staining,
the slides were deparaffinized using xylene and ethanol. Antigen
retrieval was performed by heating slides in a sodium citrate
buffer (10 mM Sodium citrate, pH 6.0, 0.05% Tween-20).
For DAB-Immunostaining
Tissues were processed with deparaffinization and antigen
retrieval. Endogenous peroxidases were inactivated by Peroxidase
blocking solution (200 ml TBS mixed with 3.75 ml of 30%
H2O2) for 30 min at room temperature. After washing three
times with TBS to remove peroxidase blocking solution, samples
were incubated with blocking solution (TBS with 0.1% Tween-
20 and blocked with 1.5% normal goat or horse serum)
for 1 h at room temperature. After blocking, slides were
incubated overnight at 4◦C with primary antibodies (Rabbit
anti-Iba1 1:1,000,01-19741, Wako, Japan; Goat anti-GFAP 1:400,
ab53554, Abcam; Mouse anti-MBP 1:520, sc-271524, Santa Cruz,
United States; Rat anti-mouse CD45 1:500, 103101, Biolegend,
United States), diluted in the blocking solution. The following
day, tissues were washed with TBS-T three times, then incubated
with corresponding biotinylated secondary antibodies (Vector
Laboratories, United States) diluted in blocking solution for
1 h at room temperature. Tissues were washed with TBS-T,
incubated with an avidin-biotin complex solution for 1 h, and
the resulting signal was visualized using 3, 3′-diaminobenzidine
(DAB, Vector Laboratories Inc., United States). Slides were
scanned using a Pannoramic 250 (3DHistech, Hungary) slide
scanner with 20× magnification and single layer focus. Scanned
slides were processed and captured images using Pannoramic
Viewer 1.15.4 (3DHistech).
Immunofluorescent Staining
Tissues were permeabilized with TBS-T (TBS with 0.1% Tween-
20) and blocked with 5% bovine serum albumin (BSA, Sigma)
for 1 h. After blocking, tissues were incubated overnight 4◦C
with primary antibodies (Mouse anti-MBP 1:520, sc-271524
Santa Cruz; Rabbit anti-Neurofilament 1:750, ab1987 Millipore,
United States; Rabbit anti-MANF 1:1,000, LS-B2688, LSBio,
United States; Goat anti-TPPP, 1:500, PA5-19243, Invitrogen,
United States) diluted in blocking solution. The next day,
tissues were washed three times with TBS-T, and incubated
for 1 h with fluorescence-conjugated corresponding secondary
antibodies (Alexa 488, 568, and 647, 1:200, donkey anti-rabbit,
anti-goat, and anti-mouse, Thermo Fisher Scientific), diluted in
blocking solution at room temperature. Tissues were washed
and incubated with DAPI to visualize nuclear and counterstain
(1:1,000, Thermo Fisher Scientific). Laser scanning confocal
micrographs of the fluorescently labeled lumbar spinal cords were
acquired with an LSM700 (Carl Zeiss) using a LCI Plan-Neofluar
63×/1.3 Imm Corr objective with 80% glycerol.
Inflammation Scores
The inflammation scores were evaluated using hematoxylin-
eosin stained (H&E) images. Tissues were stained with H&E
to visualize infiltrated cells in spinal cords and were scanned
with a Pannoramic 250 (3DHistech, Budapest, Hungary) slide
scanner with 20× magnification and single layer focus. The
infiltration of peripheral immune cells was scored according
to an inflammatory scoring setup described earlier: (0) no
inflammation; (1) cellular infiltrate only detected in the
perivascular areas and meninges; (2) mild cellular infiltrate in
white matter areas of spinal cords; (3) moderate cellular infiltrate
in white matter areas of spinal cords (4) severe cellular infiltrate
in the whole white matter of spinal cords (Okuda et al., 2002).
Image Analysis
Image analysis was performed using Fiji image J. With tissues
DAB-stained against Iba1 or GFAP images were captured at 20×
magnification and stained areas (pixel value) were quantified
from four to six images per animal. For CD45, CD45-positive
cells were from four images per animal. With tissues stained
using immunofluorescent antibodies, four fluorescence images
were captured in the white matter of the spinal cords at
63× magnification. The pixel area of each target protein was
quantified and compared against the mean result from the
naïve control group. The colocalization of MANF and MBP or
MANF and TPPP was evaluated using the colocalization plug-in
(Nam et al., 2015).
Statistical Analysis
All values were presented as mean ± standard error of the mean
(SEM). Statistical significance was determined by unpaired t-tests
for single comparisons, or two-way ANOVA followed by Tukey’s
post hoc test or Sidak’s post hoc test for multiple comparisons.
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All statistical analysis was performed using GraphPad8 Prism
software (GraphPad Software, United States).
RESULTS
Dexamethasone Postpones Clinical
Signs and Ameliorated Motor Behavior
Dysfunction in EAE
To explore the effect of dex in EAE, C57BL/6 immunized with
MOG35−55 underwent a 28-day testing period as described by the
experimental design timeline in Figure 1A. Before the induction
of EAE, mice underwent testing with the rotarod behavioral test
for 3 days, based on which mice were balanced into treatment
groups (naïve, EAE + Veh and EAE + Dex). We observed
first clinical signs (clinical score 0.5–1.0) in EAE + Veh mice
at 8 days post-immunization (dpi). The disease course reached
its peak (clinical score 3.0–4.0) at 14 dpi, and continued until
28 dpi, at which point the last animals were sacrificed. Animals
in the naïve group did not display clinical signs. Animals in the
EAE + Dex group showed onset of clinical signs at 14 dpi and
reached peak clinical scores at 23 dpi. Thus, dex-treatment in
EAE mice postponed the onset of EAE by an average of 6 days
compared to EAE + Veh mice (Figure 1B). Gain or loss of body
weight is another clinical sign of the EAE mice model: the body
weight for both EAE induced groups was significantly reduced
FIGURE 1 | Dexamethasone delayed the manifestation of clinical signs and reduced motor behavior dysfunction in EAE mice. (A) Diagram of the experiment design.
To induce EAE, C57BL/6 were immunized with MOG35-55/CFA and Pertussis toxin (PTX). EAE mice received dexamethasone (100 µg) or vehicle (PBS)
intravenously (i.v. tail vein) every second day. Mice were transcardially perfused after behavioral experiments at an interval of 7 days. (B) Mean clinical scores for each
day from immunization (0 dpi) to 28 dpi. At ***P < 0.001, treatment with dexamethasone significantly delayed the manifestation of clinical signs compared to the
EAE + Veh group at 9–22 dpi. Mean ± SEM, n = 4–26. (C) Gain/loss of body weight. At ***P < 0.001, treatment with dexamethasone significantly reduced body
weight loss compared to the EAE + Veh group at 12 dpi to 20 dpi. Mean ± SEM, n = 4–26. (D) Latency to fall during the Rotarod test was recorded at 7, 14, 21, and
28 dpi. (E) Distance traveled and (F) vertical counts (rearing-up) was recorded with the open-field test at 7, 14, 21, and 28 dpi. (D,E) n.s; non-significant, *P < 0.05,
**P < 0.01, and ***P < 0.001, Mean ± SEM. n = 7–27 (7 dpi), n = 7–21 (14 dpi), n = 4–14 (21 dpi), and n = 4–8 (28 dpi). (B–F) 2-way ANOVA was used followed by
Tukey’s post hoc test for multiple comparisons. Data from 4 repeated experiments.
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compared to the naïve group from 4 dpi onward, while the naïve
group increased in body weight throughout the experiment. The
loss of body weight before the onset of the disease may be partially
caused by chronic stress caused by repeated iv injections, as it
occurs in both EAE groups despite different delayed onset in
dex-treated animals. From 11 to 18 dpi, dex-treated mice lost
significantly less weight than the EAE+ Veh group (Figure 1C).
Rotarod and open-field tests are widely used to evaluate motor
coordination in rodent models of CNS disease, including EAE
(Dutra et al., 2013). To study motor behavior, we carried out
the Rotarod and open-field testing at 7, 14, 21, and 28 dpi
(Figure 1A). The Rotarod test for EAE + Veh mice showed
robust motor deficits at 7 dpi, and near total performance loss
at 14, 21 and 28 dpi. In contrast, treatment with dex inhibited
loss of motor function at 7 and 14 dpi, but not at 21 and
28 dpi (Figure 1D). In parallel with rotarod behavior, the total
travel distance and the number of vertical counts (representing
mice rearing up) were significantly decreased in EAE + Veh
mice at 7, 14, 21, and 28 dpi. Treatment with dexamethasone
improved travel distance and vertical counts significantly at 7,
14 dpi (Figures 1E,F), but had no effect at 21 and 28 dpi.
Dexamethasone Delays Myelin and Axon
Loss, as Well as Peripheral Immune Cell
Infiltration at Early Stages of EAE
Infiltration of immune cells to the CNS across the blood-
brain-barrier is the primary driver of demyelination and
neurodegeneration in EAE (Reich et al., 2018). To observe
the effects of dex-treatment on the immunopathogenesis of
EAE in a time-dependent manner, animals from each group
were sacrificed at 7, 14, 21, and 28 dpi, and their lumbar
spinal cords visualized using various immunohistochemical
methods (Figure 2A). MBP-positive surface areas were shown to
significantly decrease in a time-dependent manner in EAE+Veh
animals compared to naïve controls. In contrast, dex-treatment in
EAE mice protected lumbar spinal cords against demyelination at
7 and 14 dpi, but not at 21 and 28 dpi (Figures 2B, 4A).
A small degree of infiltration by peripheral immune cells in
EAE + Veh mice was detected at 7 dpi, with inflammatory
scores increasing each week throughout the experiment. In
EAE mice treated with dex, infiltration was first detected at
14 dpi and increased progressively through the end of the
experiment, showing a trend consistent with the concept of
dex delaying disease onset by a week (Figure 2C). Similarly,
EAE + Veh animals showed a progressive loss of neurofilament-
positive axons, whereas treatment with dex preserved axons at
7 and 14 dpi, before the onset of rapid axon loss at 21 and
28 dpi (Figure 2D).
Dexamethasone Delays the
Neuroinflammatory Activation of
Microglia, Leukocytes, and Astrocytes
The neuroinflammatory activation of resident glial cells is
thought to contribute to neurodegeneration in EAE (Matsumoto
et al., 1992). Visualization of Iba1 in lumbar spinal cords by
DAB-stain showed a progressive increase in neuroinflammatory
microglial activation throughout the disease, unlike in naïve
controls. In mice treated with dex this increase was delayed at 7
and 14 dpi, but microglial activation reached similarly high levels
at later timepoints (Figures 3A,B). The distribution of leukocytes
was determined by analyzing slides stained for leukocyte
common antigen CD45. As with Iba-1 immunostaining,
increased counts of cell positive for CD45 were detected at
7 dpi (though still small), reached peak levels at 14 dpi, and
remained at peak levels until the end of experiment, compared
to naïve controls. The cell counts of CD45-positive cells in
mice treated with dex were small at 7 dpi, and significantly
smaller than in EAE + Veh mice at 14 dpi (Figures 3A,C). By
staining for GFAP, an intermediate filament-III protein that is
upregulated in astrocytes during neuroinflammation, a sustained
increase in astrocyte activation could be detected in EAE + Veh
animals throughout the disease. This increase was significantly
ameliorated by dex-treatment at 7, 14, and 21 dpi (Figures 3A,D).
Dexamethasone Significantly Boosts
MBP-Positive Myelin Sheath
MANF-Levels During Early Stages of EAE
NTFs play an important role in neuroinflammation. Therapeutic
potentials of NTFs such as CNTF have been studied using the
EAE mouse model (Linker et al., 2002). MANF, an endogenous
protein with NTF-properties known to possess neuroprotective
effects in animal models of Parkinson’s disease (PD) and diabetes
(Voutilainen et al., 2009; Lindahl et al., 2014; Pöyhönen et al.,
2019), has not been studied using EAE before. In order to
investigate whether MANF is associated with EAE, we performed
a double staining in lumbar spinal cords against MBP and MANF.
We found that dex-treatment during EAE increased MANF-
positive areas significantly in the white matter compared to the
EAE+Veh group at 7 and 14 dpi, but this effect was progressively
reduced at later time points (Figures 4A,B). MANF-positive
areas in EAE animals remained at similar levels as those in
naïve controls at 7 dpi, but were dampened at 14, 21, and
28 dpi. Similarly, analysis of colocalization showed that MANF
colocalized with MBP in both EAE+Veh and EAE+Dex groups
at the same levels as naïve controls at 7 dpi, but this colocalization
was reduced at all later timepoints in the EAE + Veh group
(Figures 4A,C). The colocalization of MANF and MBP in dex-
treated mice was significantly higher than in EAE + Veh mice
at 14 dpi and at similar levels as the EAE + Veh group at
21 and 28 dpi. The colocalization of MANF with the mature
oligodendrocyte cell body marker TPPP was not affected by
treatment with dex indicating that dex only increased MANF-
levels in myelinated axons, the primary targets of autoimmunity
in EAE (Figures 4D,E).
In order to test whether dex affects the expression of MANF in
naïve mice, we treated healthy C57BL/6 mice with 100 µg of dex
i.v., and sacrificed them 0.5, 1, 3, and 6 h later (Supplementary
Figure 2). Treatment with dex did not show a statistically
significant increase in either MANF or MBP surface area,
suggesting that the boosting effect of dex on MANF occurs
specifically during the early stages of EAE.
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FIGURE 2 | Dexamethasone inhibited myelin and axon loss, as well as immune cell infiltration in the early stage of EAE. (A) Representative images from MBP (Left),
Hematoxylin-Eosin (H&E, Center), and neurofilament (Right; Green: Neurofilaments, Cyan: DAPI nuclear stain) immunostained mouse spinal cords at 7, 14, 21, and
28 dpi. (B) Quantification of MBP area at each time point. ***P < 0.001, Mean ± SEM. n = 5–8 per each group. (C) Evaluation of inflammation score from
hematoxylin-eosin staining. *P < 0.05, **P < 0.01, and ***P < 0.001, Mean ± SEM, significance base on unpaired t-test. n = 5–7 per each group. (D) Quantification
of the number of neurofilament-positive axons. ***P < 0.001, Mean ± SEM. n = 5–7 per each group. (B,D) 2-way ANOVA followed by Sidak’s post hoc test for
multiple comparisons. Scale bar; 50 µm for MBP, H&E. 20 µm for neurofilament. Data from 4 repeated experiments.
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FIGURE 3 | Dexamethasone attenuated neuroinflammatory activation of microglia, leukocytes, and astrocytes during the early stage of EAE. (A) Representative
images for Iba-1 (Left), CD45 (Center), and GFAP (Right) from immunostained mouse spinal cords at 7, 14, 21, and 28 dpi. (B) Quantification of Iba-1 area in each
time point. *P < 0.05, and ***P < 0.001, Mean ± SEM. n = 5–6 per each group. (C) Quantification of the number of CD45-positive cells in each time point.
*P < 0.05, and **P < 0.01, Mean ± SEM. n = 5–8 per each group. (D) Quantification of GFAP area in each time point. **P < 0.01, and ***P < 0.001, Mean ± SEM,
n = 5–7 per each group. (B–D) 2-way ANOVA followed by Sidak‘s post hoc test for multiple comparisons. Scale bars: 200 µm for CD45; 50 µm for Iba-1, GFAP; 10
µm for enlarged Iba-1, GFAP and CD45. Data from 4 repeated experiments.
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FIGURE 4 | MANF levels within myelin sheaths, but not the cell bodies of mature oligodendrocytes, were increased by dexamethasone in the early stage of EAE.
(A) Representative fluorescence images of MBP (Green), MANF (Magenta), and DAPI (Blue) in the white matter of mouse spinal cords at 7, 14, 21, and 28 dpi.
Enlarged images were taken from boxed areas within merged images. (B) Quantification of MANF area in each time point. ***P < 0.001, Mean ± SEM. n = 5–8 per
each group. (C) Quantification of MANF-expression area within MBP-positive areas at each time point. ***P < 0.001, Mean ± SEM, n = 5–7 per each group.
(D) Representative fluorescence images of TPPP (Red), MANF (Light gray), and DAPI (Blue) in the white matter of mouse spinal cords at 7, 14, 21, and 28 dpi.
(E) Quantification of MANF-expression area within TPPP-positive areas at each time point. n = 5–8 per each group. (B,C,E) 2-way ANOVA followed by Sidak’s
post hoc test for multiple comparisons. Scale bars: 200 µm for MBP, MANF, and Merge; 10 µm for enlarged imaged. Data from 4 repeated experiments.
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Endoplasmic reticulum (ER) stress and the unfolded protein
response (UPR) play important role in EAE, contributing to
oligodendrocyte death and glial activation (Lin and Popko, 2009;
Reverendo et al., 2019). MANF, a UPR-induced protein with
NTF-properties, is believed to be expressed in tissues such as
the spinal cord white matter as a response to intense ER stress
(Danilova et al., 2019). If MANF is an indicator of ER stress,
it would be reasonable to assume that dex increased expression
of MANF by inducing ER stress in the earlier timepoints of
the disease. However, analysis of the expression of GRP78, an
upstream regulator of UPR, in lumbar white matter showed
no difference between EAE and dex groups in UPR activation
(Supplementary Figure 3).
MANF Delays Disease Progression and
Protects Motor Behavior in Early Stages
of EAE
In order to study the role of MANF in EAE, another 28-day
testing period was performed on C57BL/6 mice immunized with
MOG35−55 (Figure 5A), replacing dex with human MANF.
While all animals showed a similar disease onset at day 8, mice
that were treated with either 1.5 or 3 µg of hMANF i.v. displayed
a significant plateau in the progression of clinical signs before
week 2 (11–14 dpi for 1.5 µg mice and 13–14 dpi for 3 µg
mice). After day 14, the clinical score immediately caught up
with vehicle treated mice (Figure 5B). No difference was detected
in body weight loss between hMANF and vehicle treated mice
(Figure 5C). As shown in earlier Figures 1D–F, EAE mice show
decreased performance and mobility as compared to healthy
controls at 7 dpi, just before the onset of clinical signs. EAE
mice that were treated with either dose of hMANF showed a
significantly better capability to remain on a rotarod (Figure 5D)
at 7 dpi. Similarly, both doses of hMANF significantly increased
distance traveled and vertical counts performed during open
field-testing at 7 dpi (Figures 5E,F). No effect on rotarod or open
field performance was detected at 14–28 dpi.
DISCUSSION
This study further showed that the intravenous administration of
dex to MOG33−55/CFA induced mice postpones motor function
loss in early stages of the disease. Moreover, dex was efficient
at suppressing histological and immunological features of EAE,
including the degeneration of myelin, axon loss and immune
cell infiltration as well as the proinflammatory activation of
microglia and astrocytes. Demyelination and the resulting axonal
degeneration (Papadopoulos et al., 2006) of the CNS is invariably
linked to immune cell infiltration in the EAE model of MS
(Yednock et al., 1992; Ransohoff, 2012). Dex is believed to inhibit
this process by reducing the number of circulating immune
cells (Nguyen et al., 1997; Chen et al., 2006). This is further
validated by our results, which showed that motor function
loss, demyelination, proinflammatory glial activation and axonal
degeneration in EAE mice treated with dexamethasone mirrored
the progression of immune cell infiltration in the lumbar spinal
cord (Figures 1–3).
Interestingly, our results showed that dex-treated EAE mice
eventually reached similar clinical scores, axonal degeneration
and spinal cord neuroinflammation, as vehicle-treated mice.
This finding differs from several other studies, which generally
show a more sustained neuroprotection from treatment with
dex in EAE (Donia et al., 2010; Dos Santos et al., 2019). The
difference may be due to different methods of administration,
as dex is usually given i.p and not i.v., though it is not
clear why intravenously given dex would lose effectiveness.
The increased bioavailability in intravenous administration may
lead to increased development of glucocorticoid resistance in
circulating immune cells. Glucocorticoid resistance reduces the
therapeutic effect of exogenous dex, likely via a downregulation
of glucocorticoid receptors in target cells (Gold et al., 2012).
The development of glucocorticoid resistance is an important
factor in the clinical treatment of neuroinflammatory conditions
with glucocorticoids such as dexamethasone, and EAE may be
a practical model for studying its development (Hoepner et al.,
2019). Alternatively, it is possible that intravenously administered
dex is processed and excreted out of the body faster than in ip.
reducing its therapeutic efficiency as EAE gains severity.
NTFs are abundantly expressed in a variety of cell types
in the brain (Poo, 2001), and play an important role in both
neurons and other cells of the CNS. The function and role
of neurotrophic factors has been studied in both EAE mice
and human MS patients. Reducing CNTF-production has led
to poorer outcomes in EAE experiments (Linker et al., 2002),
and the major neurotrophic factor BDNF has been reported to
be highly expressed in infiltrated immune cells in MS patient
brain tissue (Stadelmann et al., 2002). While glucocorticoids
such as dexamethasone are generally though to play an anti-
inflammatory role in EAE, dexamethasone has also been found
to promote TrkB signaling, a known action mechanism of BDNF
(Jeanneteau et al., 2008; Casarotto et al., 2021). Accordingly,
treatment with dex has showed trophic effects on neurons
both in vivo and in vitro, suggesting that in addition to
its immunosuppressive abilities, dex can activate neurotrophic
factor signaling in EAE.
In our study, we focused on the time-dependent expression
of the novel neurotrophic factor MANF in EAE. We found that
MANF was strongly expressed in the white matter of spinal cords
in EAE mice, and that expression of MANF significantly decrease
in a time-dependent manner in EAE. This decrease was in line
with both the decrease in myelination, and the infiltration of
immune cells in EAE mice (Figure 4). Interestingly, expression of
MANF in spinal cord white matter were significantly increased by
dex-treatment in early stages of EAE. This increased expression
was highly co-localized with MBP-positive myelinated axons, the
main targets of autoimmunity in EAE, while the colocalization of
MANF with MBP was reduced along with MANF-levels during
the peak of the disease. This poses the interesting question of
whether this decrease in axonal MANF is a cause or result of
axonal demyelination and degeneration.
As mentioned before, MANF is generally associated with
activation of the UPR due to intense ER stress (Voutilainen et al.,
2015). The UPR is an adaptive response to the stress caused by
an accumulation of misfolded proteins in the ER of affected cells.
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 July 2021 | Volume 15 | Article 640084
fncel-15-640084 July 1, 2021 Time: 16:12 # 10
Nam et al. MANF in Early-stage EAE
FIGURE 5 | MANF ameliorated clinical signs and reduced motor behavior dysfunction during the early stage of EAE. (A) Diagram of the experiment design. To
induce EAE, C57BL/6 were immunized with MOG35-55/CFA and Pertussis toxin (PTX). Mice received human MANF (1.5 or 3 µg) or PBS as a vehicle control
intravenously (i.v. tail vein) every second day. Mice performed behavioral tests at an interval of 7 days. (B) Mean clinical scores for each day from immunization (0 dpi)
to 28 dpi. At *P < 0.05, **P < 0.01, and ***P < 0.001, treatment with hMANF (1.5 µg) significantly delayed clinical signs manifestation compared to the EAE group
at 11 dpi to 14 dpi, ##P < 0.01, and ###P < 0.001, treatment with hMANF (3 µg) significantly delayed clinical signs manifestation compared to the EAE group at 13
and 14 dpi. Mean ± SEM, n = 9–10. (C) Gain/loss of body weight. Mean ± SEM, n = 9–10. (D) Latency to fall during the Rotarod test was recorded at 7, 14, 21,
and 28 dpi. (E) Distance traveled and vertical counts (rearing-up) was recorded with the open-field test at 7, 14, 21, and 28 dpi. (D–E) ***P < 0.001, Mean ± SEM.
n = 9–10. (B–F) 2-way ANOVA was used followed by Tukey’s post hoc test for multiple comparisons. Data from a single independent experiment.
It triggers both protective and apoptotic signals, and contributes
to neurodegeneration in both MS and its disease models (Stone
and Lin, 2015). Dex has an interesting relationship with ER
stress and the UPR. In glomerular diseases such as nephrotic
syndrome, it seems to reduce ER stress as a result of binding to
glucocorticoid receptors (Fujii et al., 2006), whereas in a mouse
model of asthma treatment, dex did not affect ER stress levels
(Kim and Lee, 2015). In a murine glaucoma model topical eye
treatment with dex can even be used to induce ER stress to
an extent that leads to axonal degeneration (Zode et al., 2014).
No results associating dex with the UPR in EAE models have
currently been published. In this study we focused on the glucose-
regulated protein 78 kDa (GRP78) to analyze the activation of the
UPR in a time-dependent manner in EAE. GRP78, also known as
Binding immunoglobin Protein (BiP), is an ER-resident protein
that plays a critical role in the ER stress response (Casas, 2017).
Although the mechanisms for the regulation and secretion of
MANF are not completely understood, in Neuro2a cells MANF
has been shown to be regulated in the ER by GRP78 (Oh-Hashi
et al., 2012). In this report, we found that while expression of
GRP78 was elevated in both EAE groups at the beginning of
the experimental period, it was not affected by treatment with
dex. Based on this observation, it seems that while an increase
in MANF-expression is a result of treatment with dex during
EAE, it is not linked to an increase in ER stress or activation
of the UPR. In addition to its effects on ER stress, MANF is
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known to regulate immune cell activation (Neves et al., 2016), and
has recently been discovered to be capable of suppressing NF-κB
signaling by binding to neuroplastin on the cell membrane (Yagi
et al., 2020). Thus, increasing MANF-expression may be another
way for dex to regulate immune responses.
In order to test whether MANF itself can be therapeutic in
EAE, we gave EAE-induced mice hMANF intravenously. This led
to improved performances in behavioral tests at 7 dpi, before any
signs of paralysis had manifested. Interestingly, the therapeutic
effect of MANF on the clinical score was limited to 11–14 dpi,
during which treatment with MANF halted the progression of
paralysis. As a 20 kDa protein, MANF has poor bioavailability
to the CNS. As the onset of EAE is associated with a significant
increase in blood-brain- barrier (BBB) permeability (Wolburg
et al., 2003; Bennett et al., 2010), it is possible that the breakdown
of the endothelial BBB allows for a therapeutic time window
during which administered exogenous MANF can access the
CNS. This would need to be verified by further studies, as it
doesn’t explain the positive behavioral effects before onset of
paralysis, when immune cell infiltration is still scarce. The timing
could also be explained by other factors, such as MANF having
an anti-inflammatory effect on peripheral immune cells during
the onset of the disease.
In summary, we proved the neuroprotective effect of the
glucocorticoid dex in EAE mice immunized with MOG35−55
in a time-dependent manner. We showed that in the early
stage of EAE, dex delays motor dysfunction and clinical
disease onset. Additionally, treatment with dex postponed
general histological features of EAE, including demyelination,
axonal loss, immune cell infiltration, and neuroinflammatory
glial cell activation. Interestingly, we observed an increased
expression of MANF lumbar spinal cord myelinated axons
during EAE, which was strongly elevated by dex in early stages
of the disease. We then showed that intravenously injected
hMANF reduced behavioral dysfunction and inhibited the
progression of clinical signs at the early stage of the disease.
These results indicate that MANF may play an important
role in EAE, and should be considered a potential drug
candidate in the treatment of MS. A better understanding
of the interplay between MANF and neuroinflammatory
responses is needed for the study of neuroinflammatory diseases
such as MS.
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Supplementary Figure 1 | Mean body weight for each experimental group
during EAE. Mice were weighed each day during the study regarding the effect of
dexamethasone in EAE, and mean group weights were used to calculate the dose
of dexamethasone. Mean ± SEM, n = 7–26. Data from 4 repeated experiments.
Supplementary Figure 2 | A single dose of dexamethasone did not affect MANF
and MBP in naïve mice. (A) Diagram of the experiment design. All mice received
dexamethasone (100 µg) or vehicle (PBS) intravenously (i.v. tail vein). Mice were
transcardially perfused at an interval of 0.5, 1, 3, and 6 h. (B) Quantification of
MANF and MBP area in each time point. Mean ± SEM. n = 5–6 per each group.
(C) Representative fluorescence images of MBP (Green), MANF (Magenta), and
DAPI (Blue) in the white matter of mouse spinal cords at 0.5, 1, 3, and 6 h. Scale
bars: 10 µm. Data from a single independent experiment.
Supplementary Figure 3 | GRP78 in the white matter of mouse spinal cords was
not affected by dex-treatment in the EAE mouse model. Spinal cord sections were
collected from EAE + Veh and dex-treated EAE mice at 7, 14, 21, and 28 dpi, in
order to investigate whether GRP78 is regulated by dexamethasone or EAE
progression in a time-dependent manner. (A) Representative fluorescence images
show the expression of GRP78 (Red) and DAPI (Cyan) in the white matter of mice
spinal cords. Enlarged images are taken from boxed areas from merged images.
(B) Quantification of GRP78 area in each time point. Mean ± SEM. n = 5–8 per
each group. Scale bars: 25 µm for GRP78/DAPI, 10 µm for enlarged images.
Data from 4 repeated experiments.
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